194 related articles for article (PubMed ID: 11764864)
21. Relationship between myalgias/arthralgias occurring in patients receiving quinupristin/dalfopristin and biliary dysfunction.
Raad I; Hachem R; Hanna H
J Antimicrob Chemother; 2004 Jun; 53(6):1105-8. PubMed ID: 15128724
[TBL] [Abstract][Full Text] [Related]
22. Linezolid and quinupristin/dalfopristin: novel antibiotics for gram-positive infections of the skin.
Schweiger ES; Scheinfeld NS; Tischler HR; Weinberg JM
J Drugs Dermatol; 2003 Aug; 2(4):378-83. PubMed ID: 12884459
[TBL] [Abstract][Full Text] [Related]
23. Quinupristin-dalfopristin: an overview.
Delgado G; Neuhauser MM; Bearden DT; Danziger LH
Pharmacotherapy; 2000 Dec; 20(12):1469-85. PubMed ID: 11130220
[TBL] [Abstract][Full Text] [Related]
24. Arthralgias and myalgias related to quinupristin-dalfopristin administration.
Olsen KM; Rebuck JA; Rupp ME
Clin Infect Dis; 2001 Feb; 32(4):e83-6. PubMed ID: 11181142
[TBL] [Abstract][Full Text] [Related]
25. High-frequency recovery of quinupristin-dalfopristin-resistant Enterococcus faecium isolates from the poultry production environment.
Hayes JR; McIntosh AC; Qaiyumi S; Johnson JA; English LL; Carr LE; Wagner DD; Joseph SW
J Clin Microbiol; 2001 Jun; 39(6):2298-9. PubMed ID: 11376075
[TBL] [Abstract][Full Text] [Related]
26. Use of streptogramin growth promoters in poultry and isolation of streptogramin-resistant Enterococcus faecium from humans.
Kieke AL; Borchardt MA; Kieke BA; Spencer SK; Vandermause MF; Smith KE; Jawahir SL; Belongia EA;
J Infect Dis; 2006 Nov; 194(9):1200-8. PubMed ID: 17041845
[TBL] [Abstract][Full Text] [Related]
27. Quinupristin/dalfopristin.
Med Lett Drugs Ther; 1999 Nov; 41(1066):109-10. PubMed ID: 10987009
[No Abstract] [Full Text] [Related]
28. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
Scheinfeld N
J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
[TBL] [Abstract][Full Text] [Related]
29. Experience with quinupristin/dalfopristin in treating infections with vancomycin-resistant Enterococcus faecium in children.
Gray JW; Darbyshire PJ; Beath SV; Kelly D; Mann JR
Pediatr Infect Dis J; 2000 Mar; 19(3):234-8. PubMed ID: 10749466
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of quinupristin/dalfopristin for treatment of invasive Gram-positive infections in pediatric patients.
Loeffler AM; Drew RH; Perfect JR; Grethe NI; Stephens JW; Gray SL; Talbot GH
Pediatr Infect Dis J; 2002 Oct; 21(10):950-6. PubMed ID: 12394819
[TBL] [Abstract][Full Text] [Related]
31. Quinupristin-dalfopristin.
Bryson HM; Spencer CM
Drugs; 1996 Sep; 52(3):406-15. PubMed ID: 8875130
[TBL] [Abstract][Full Text] [Related]
32. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia.
Erlandson KM; Sun J; Iwen PC; Rupp ME
Clin Infect Dis; 2008 Jan; 46(1):30-6. PubMed ID: 18171210
[TBL] [Abstract][Full Text] [Related]
33. In vitro activities of cefotaxime, vancomycin, quinupristin/dalfopristin, linezolid and other antibiotics alone and in combination against Propionibacterium acnes isolates from central nervous system infections.
Mory F; Fougnot S; Rabaud C; Schuhmacher H; Lozniewski A
J Antimicrob Chemother; 2005 Feb; 55(2):265-8. PubMed ID: 15590714
[TBL] [Abstract][Full Text] [Related]
34. Molecular analysis of streptogramin resistance in enterococci.
Werner G; Klare I; Witte W
Int J Med Microbiol; 2002 Jul; 292(2):81-94. PubMed ID: 12195739
[TBL] [Abstract][Full Text] [Related]
35. Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline.
Raad I; Hachem R; Hanna H; Girgawy E; Rolston K; Whimbey E; Husni R; Bodey G
Antimicrob Agents Chemother; 2001 Nov; 45(11):3202-4. PubMed ID: 11600379
[TBL] [Abstract][Full Text] [Related]
36. [Gram-positive bacterial infections resistant to antibiotic treatment].
Utili R
Ann Ital Med Int; 2001; 16(4):205-19. PubMed ID: 11799629
[TBL] [Abstract][Full Text] [Related]
37. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination.
Matsumura S; Simor AE
Clin Infect Dis; 1998 Dec; 27(6):1554-6. PubMed ID: 9868693
[No Abstract] [Full Text] [Related]
38. Combining quinupristin/dalfopristin with other agents for resistant infections.
Brown J; Freeman BB
Ann Pharmacother; 2004 Apr; 38(4):677-85. PubMed ID: 14990776
[TBL] [Abstract][Full Text] [Related]
39. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group.
Nichols RL; Graham DR; Barriere SL; Rodgers A; Wilson SE; Zervos M; Dunn DL; Kreter B
J Antimicrob Chemother; 1999 Aug; 44(2):263-73. PubMed ID: 10473234
[TBL] [Abstract][Full Text] [Related]
40. Gram-positive bacterial resistance. A challenge for the next millennium.
Bassetti M; Melica G; Cenderello G; Rosso R; Di Biagio A; Bassetti D
Panminerva Med; 2002 Sep; 44(3):179-84. PubMed ID: 12094131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
